The effect of pyridoxine supplementation on plasma lipoproteins and its relationship with atherogenic risk

Biomedical Letters

Volumn 59, Issue 231, 1999, Pages 7-14

  Sermet A ^a   Atmaca, M ^a   Diken, H ^a   Kelle, M ^a   Deniz, B ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Atherogenic risk; Cholesterol; Lipoproteins; Pyridoxine HCL

Indexed keywords

EID: 0033241642     PISSN: 0961088X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. AUDET A. and Lupien P. J. 1972. Metabolism des lipoproteins en carence de pyridoxine. Rev. Can. Biol. 31 171-80.
2. CARTER C. W. and Phizackerley P. J. R. 1951. The influence of pyridoxine on fat metabolism in the rat. Biochem. J. 49 227-32.
3. HINSE C. M. and Lupien P. J. 1971. Cholesterol metabolism and vitamin B6. III. The stimulation of hepatic cholesterogenesis in the vitamin B6 deficient rat. Can. J. Biochem. 49 933-5.
4. HUBER A. M., Gershoff S. N. and Hegsted D. M. 1964. Carbohydrate and fat metabolism and response to insulin in vitamin B6 deficient rats. J. Nutr. 82 371-8.
5. KNIPSCHEER H. C., Kindt I., Van-den-Ende A., Nurmohamed M., Smalbraak H., Mulder W. J. and Kastelein J. J. 1997. Magnesium pyridoxal-5′-phosphate glutamate, a vitamin B6 derivative, does not affect lipoprotein levels in patients with familial hypercholesterolaemia. Eur. J. clin. Pharmacol. 51 499-503.
6. KUJALOVA V. 1971. The effect of disulfide on vitamin B6 metabolism. In Second International Symposium on Toxicology of Carbon Disulfide. Yugoslavia, Ranja Koviljac. 37 pp.
7. LLADO-CARBONELL C., Senti-Clapes M., Rubies-Prat J., Arongo-Toro O. and Gelabert-Mas A. 1995. Serum lipoprotein changes after orchidectomy and treatment with oestrogen and analogues in male Sprague-Dawley rats. Eur. J. clin. Chem. Clin. Biochem. 33 5-9.
8. LOO G. and Smith J. T. 1986. Effect of pyridoxine deficiency on phospholipid methylation in rat liver microsomes. Lipids 21 409-12.
9. MAGIDE A. A. and Myant N. B. 1975. Loss of cholesterol from muscle and skin of monkeys treated with nicotinic acid. Atherosclerosis 21 273-81.
10. MAGIDE A. A. and Myant N. B. 1974. Effect of nicotinic acid on cholesterol metabolism in monkey. Clin. Sci. Mol. Med. 46 527-38.
11. MAHLEY R. W. 1985. Atherogenic lipoproteins and coronary artery disease: concepts derived fom recent advances in cellular and molecular biology. Circulation. 72 943-8.
12. MAJOR L. F., Goyer P. F. and Maryland B. 1978. Effects of disulfiram and pyridoxine on serum cholesterol. Ann. intern. Med. 88 53-6.
13. McHENRY E. W. and Gauvin G. 1938. The B vitamins and fat metabolism. J. biol. Chem. 125 653-60.
14. MERRILL A. H. and Henderson J. M. 1987. Diseases associated with defects in vitamin B6 metabolism or utilization. Ann. Rev. Nutr. 7 137-56.
15. MYANT N. B. 1982. Cholesterol transport through the plasma. Clin. Sci. 62 261-71.
16. RADIN S. N. 1981. Extraction of tissue lipids with a solvent of low toxicity. Meth. Enzymol. 72 5-7.
17. RIPPA M. and Pontremoli S. 1969. Pyridoxal 5′-phosphate as a specific photosensitizer for histidin residues at the active site of 6-phosphogluconate dehydrogenase. Archs Biochem. Biophys. 8 112-8.
18. SATO I. 1970. A possible role of pyridoxine in lipid metabolism. J. med. Sci. 33 105-30.
19. SERFONTEIN W. J., Ubbink J. B., De Villiers L. S., Rapley C. H. and Becker P. J. 1985. Plasma pyridoxal-5 phosphate level as risk index for coronary artery disease. Atherosclerosis 55 357-61.
20. SHERMAN H. 1950. Pyridoxine in fat metabolism. Vit. Horm. 8 55-68.
21. SHIDELER C. E. 1983. Vitamin B6: an overview. Am. J. Med. Tech. 49 17-21.
22. SWELL L., Law M. D., Schools P. E. and Treadwell C. R. 1961. Tissue lipid fatty acid composition in pyridoxine-deficient rats. J. Nutr. 74 48-156.
23. TINTERA J., Leposavic L. and Milic S. 1970. Excretion of some tryptophan metabolites in man exposed to carbon disulfide. Med. Lav. 61 1.
24. TOYAM T. and Sakurai H. 1967. Ten year changes in exposure level and toxicological manifestations in carbon disulphide workers. In Toxicology of Carbon Disulphide. pp 197-204. Edited by H. Brieger and J. Teisinger. Excerpta Medica, Amsterdam.
25. VON A. B., Schimidt A. and Upmeyer H. J. 1985. Wirksamkeit und vertraglichkeit von sedalipid bei der Behandlung von hyperlipoproteinamien. Fortschr. Med. 103 1011-4.
26. WERMAAK W. J. H., Bernard H. C., Potgieter B. M. and Marx J. D. 1986. Plasma pyridoxal-5 phosphate levels in myocardial infarction. S. Afr. Med. 70 195-6.
27. WERMAAK W. J. H., Bernard H. C., Potgieter G. M. and Theron H. T. 1987. Vitamin B6 and coronary artery disease. Atherosclerosis 63 235-8.
28. 14C-mevalonate into cholesterol in the liver of rats intoxicated with carbon disulphide. Int. Arch. Arbeitsmed. 34 221-9.